<DOC>
	<DOCNO>NCT00096525</DOCNO>
	<brief_summary>RATIONALE : Biological therapy lenalidomide use different way stimulate immune system stop tumor cell grow . It may also stop growth tumor cell stop blood flow tumor . PURPOSE : This phase II trial study well lenalidomide work treat patient advance unresectable kidney cancer .</brief_summary>
	<brief_title>Lenalidomide Treating Patients With Advanced Unresectable Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine best response patient advance unresectable renal cell cancer treat lenalidomide ( CC-5013 ) . - Determine time disease progression patient treat drug . Secondary - Determine safety drug patient . OUTLINE : This open-label study . Patients receive oral lenalidomide ( CC-5013 ) daily day 1-21 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients follow 30 day every 3 month thereafter . PROJECTED ACCRUAL : A total 14-25 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma ( RCC ) Advanced unresectable disease At least 1 measurable lesion No active brain metastasis Prior brain metastasis allow provided patient treat radiotherapy surgery AND remain asymptomatic ≥ 6 month PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 mg/dL AST ALT ≤ 2 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) No hepatitis A , B , C infection Renal Creatinine ≤ 2.0 mg/dL Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No known hypersensitivity thalidomide No serious medical condition , laboratory abnormality , psychiatric illness would preclude give informed consent No malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer , carcinoma situ cervix breast , localized prostate cancer , superficial bladder cancer PRIOR CONCURRENT THERAPY : Biologic therapy No 1 prior systemic immunotherapy regimen RCC No prior lenalidomide ( CC5013 ) No prior concurrent thalidomide Chemotherapy No 1 prior systemic chemotherapy regimen RCC Endocrine therapy No 1 prior systemic hormonal therapy regimen RCC Radiotherapy See Disease Characteristics No concurrent radiotherapy Surgery See Disease Characteristics At least 4 week since prior surgery recover Other No 1 prior systemic therapy regimen RCC No concurrent anticancer therapies No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>